Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 2442 word(s) 2442 2021-11-05 04:39:23 |
2 format corrected. Meta information modification 2442 2021-11-11 04:13:30 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Panagopoulou, M. ENPP2 Methylation in Health and Cancer. Encyclopedia. Available online: (accessed on 04 December 2023).
Panagopoulou M. ENPP2 Methylation in Health and Cancer. Encyclopedia. Available at: Accessed December 04, 2023.
Panagopoulou, Maria. "ENPP2 Methylation in Health and Cancer" Encyclopedia, (accessed December 04, 2023).
Panagopoulou, M.(2021, November 10). ENPP2 Methylation in Health and Cancer. In Encyclopedia.
Panagopoulou, Maria. "ENPP2 Methylation in Health and Cancer." Encyclopedia. Web. 10 November, 2021.
ENPP2 Methylation in Health and Cancer

Autotaxin (ATX) encoded by Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) is a key enzyme in Lysophosphatidic Acid (LPA) synthesis implicated in cancer. Although its aberrant expression has been reported, ENPP2 methylation profiles in health and malignancy are not described. We examined in silico the methylation of ENPP2 analyzing publicly available methylome datasets, to identify Differentially Methylated CpGs (DMCs) which were then correlated with expression at gene and isoform levels. Significance indication was set to be FDR corrected p-value < 0.05. Healthy tissues presented methylation in all gene body CGs and lower levels in Promoter Associated (PA) regions, whereas in the majority of the tumors examined (HCC, melanoma, CRC, LC and PC) the methylation pattern was reversed. DMCs identified in the promoter were located in sites recognized by multiple transcription factors, suggesting involvement in gene expression. Alterations in methylation were correlated to an aggressive phenotype in cancer cell lines. In prostate and lung adenocarcinomas, increased methylation of PA CGs was correlated to decreased ENPP2 mRNA expression and to poor prognosis parameters. Collectively, our results corroborate that methylation is an active level of ATX expression regulation in cancer. Our study provides an extended description of the methylation status of ENPP2 in health and cancer and points out specific DMCs of value as prognostic biomarkers. 

autotaxin ENPP2 methylation cancer expression regulation

1. Introduction

ATX encoded by ENPP2 is a secreted lysophospholipase D (lysoPLD) and belongs to the ENPP (1–7) protein family [1]. ATX is responsible for the synthesis of the majority of extracellular LPA in blood. LPA acts locally upon increased ATX levels through at least six G protein-coupled receptors [2]. Increased ATX activity and levels have been correlated with several inflammatory [3] and fibroproliferative conditions [4], as well as with cancer [5]. In particular, increased expression of ATX in blood and the subsequent increase of LPA have been correlated with cancer invasiveness [6]. In addition, it has been shown that ATX expression is upregulated in cancerous [7][8] and fibrotic tissues [9].
ENPP2 contains 26 introns and 27 exons and is located in the human chromosomal region 8q24 [10], a region with frequent genetic alterations in many cancers [11]. ENPP2 is characterized by alternative splicing of mRNA. The best-known splice variants of ENPP2 are isoforms alpha, beta and gamma; between them, differences in the stability and expression pattern have been documented among several tissues [12].
Epigenetic regulation of ENPP2 has been previously reported [13]. DNA methylation, a well-studied epigenetic mechanism, can regulate gene expression [14], and aberrant gene-specific methylation has been correlated with many pathologies, such as cancer [15][16][17][18][19][20]. However, data on the methylation profile of ENPP2 in health and pathology are fragmented. A study in Biliary Atresia (BA) showed hypomethylation at four CpGs of ENPP2 promoter in the blood and liver of BA patients in relation to normal tissue and was correlated to increased ATX expression [21]. ENPP2 promoter hypermethylation and gene under-expression was found in primary invasive breast carcinomas [13]. Similarly, in breast cancer cell lines, a promoter-associated CpG (cg02156680) of ENPP2 was found highly methylated [22].
In the present study, we studied in silico the methylation of ENPP2 in health and several malignancies and correlated it with gene and isoform expression, aggressiveness and prognosis. Cancer types included in our study were chosen based on their high world incidence, mortality and prevalence [23], as well as access to readily available suitable high-throughput datasets. We examined publicly available methylation datasets from readings by the Illumina methylation bead-chip arrays found in Gene Expression Omnibus (GEO), to identify Differentially Methylated CpGs (DMCs) of ENPP2 between health and disease. Lung, prostate and liver cancer presented a greater number of Promoter Associated (PA) DMCs for ENPP2 and were further pursued using large datasets retrieved from The Cancer Genome Atlas (TCGA), which allowed DMC correlation to clinicopathological parameters and gene expression. A workflow of our study is presented in Figure 1.
Figure 1. Workflow of the study of ENPP2. Created with (Agreement number: UW22ZTY5U7) (accessed on 24 September 2021). Abbreviations: GEO: Gene Expression Omnibus, DMCs: Differential Methylated CpG sites, TF: Transcription Factor, TCGA: The Cancer Genome Atlas, LC: Lung Cancer, PC: Prostate Cancer, HCC: Hepatocellular Carcinoma, ATX: Autotaxin.

2. Current Insights

ATX encoded by ENPP2 is a secreted glycoprotein that forms LPA [24]. The ATX-LPA axis is related to many physiological processes, including embryonic development and wound healing. Dysregulation of ATX expression is connected with various pathological conditions such as cancer, inflammatory diseases and fibrosis [3][4][5]. The exact mechanism by which ENPP2 expression is regulated is still not fully understood, whereas recently, it has been proved that ENPP2 is prone to epigenetic alterations [13]. Still, very little information is available about its DNA methylation pattern and the consequent impact in gene expression in health and human pathology.
In the present study we adopted a bioinformatic in silico approach using publicly available datasets from healthy tissues and different cancer tissues and cell lines to analyze methylation patterns of ENPP2. Our analysis showed a consistent methylation pattern throughout the gene’s regions across human tissues, i.e., increased methylation in the gene body and decreased methylation in TSS and the 1st exon. Given the fact that ENPP2 is expressed in almost all tissues and biological fluids [12][25][26], we can postulate that the decreased methylation in the TSS and 1st exon is associated with the active transcription of the gene in most human tissues.
Analysis of cancer datasets revealed aberrant ENPP2 methylation, showing a malignant-specific profile throughout different cancer types. In general, methylation was increased in the TSS and 1st exon, regions known to hold an important role in gene expression, and decreased in the gene body region. A large number of DMCs were identified between malignant and respective benign tissues. Most importantly, all six DMCs of ENPP2 located at TSS in the promoter or at the 1st exon showed increased methylation across different cancer types, including HCC, melanoma, CRC, LC and PC. These results corroborate and expand recent observations showing a hypermethylated ENPP2 promoter in primary tumors of LC and squamous cell carcinoma patients [27] and in breast cancer [13][22][28].
Based on these interesting observations, we next performed in silico analysis of ENPP2 methylation in datasets retrieved from the TCGA, focusing on those cancer types presenting the greatest number of DMCs, i.e., LC, PC and HCC. TCGA datasets are generally larger compared to those of other research efforts, allowing comparisons of stronger statistical relevance, and most significantly, they contain several clinical and demographic parameters of each patient. In addition, the datasets selected included also mRNA expression data and were therefore suitable for addressing an important objective of this study, i.e., if aberrant methylation is correlated to gene expression. Methylation, clinical and expression data were recovered for the three cancer types. Differential methylation analysis of ENPP2 revealed that all emerged DMCs identified in transcription-related (TSS and 1st exon) regions were hypermethylated in all three cancers compared to healthy controls, confirming the analysis of the GEO datasets. In addition, the majority of DMCs located at the gene body were hypomethylated in the studied cancers in relation to controls. mRNA levels were decreased in PC and LC in relation to normal tissues. Collectively, our results indicate that the increased methylation of PA and 1st exon CGs is correlated with decreased expression in lung and prostate cancer. This is in line with previous studies in LC and BC showing that ENPP2 is hypermethylated in tumor tissues in relation to normal, causing down regulation in gene expression [13][27]. In PC, ATX protein was not or was weakly expressed in non-neoplastic epithelial cells and in high-grade intra-epithelial neoplasia, while in cancer cells ATX was only expressed in half of the tumors and was correlated with adverse tumor parameters [29]. A relevant study in LC showed that ATX protein expression and activity was increased in LC tissues and sera [30]. As far as HCC is concerned, our analysis showed upregulation of expression in HCC in relation to normal liver, showing a TSS and 1st exon methylation-independent and a cancer type-specific role of ENPP2 expression regulation. In a previous study, ATX overexpression in HCC tissues was correlated with inflammation and liver cirrhosis. In addition, liver cancer cell lines presented stronger ATX expression in relation to normal hepatocytes [31]. It should be noted that many authors have demonstrated that the relationship between mRNA expression and protein differs in many cancers. It has been reported in lung cancer and glioblastoma that, for many genes, mRNA expression is lower but protein levels are higher compared with the control [32][33][34][35].
In agreement with the above findings, analysis using the UALCAN database showed that ENPP2 is hypermethylated and under-expressed in LC and PC, suggesting that DNA methylation regulates expression in LC and PC. However, no regulatory relation was observed between methylation and expression in HCC, as both were upregulated, pointing again to a cancer-specific methylation-independent ENPP2 regulation. Different mechanisms between cancer types are common. Here, our presented results from the cancer types studied indicate a cancer type-specific profile of ENPP2 methylation rather than a similar pan-cancer dysregulation. Without availability of suitable methylome datasets or targeted methylation studies of ENPP2 in each different cancer type, we cannot extrapolate conclusions between cancers.
The same correlation pattern was noticed for ENPP2 isoforms in all cancer types studied. Interestingly, there was a significant negative correlation between mRNA expression (gene and isoform alpha and beta) and promoter methylation in four CGs (cg02156680, cg02709432, cg04452959 and cg06998282) in PRAD. In LC samples, the methylation of cg06998282 and cg02709432 was negatively correlated with the expression of ENPP2 and also with isoform beta and gamma. Finally, in the case of HCC, only the methylation of cg06998282 was negatively correlated with the expression of ENPP2 and isoform beta. The above findings indicate that the promoter methylation of specific CGs is negatively correlated with ENPP2 and isoform expression differs between cancers, with cg02709432 being a common site in PC and LC but not in the case of HCC. This CG is located at a site that can bind E2F-1 TF, which has been shown to be inhibited by CG methylation [36], and Sp1 TF, which has been found to regulate ENPP2 transcription [37]. Thus, we hypothesized that as the level of methylation increases, methylation of cg02709432 hinders the binding of the TFs to the promoter, thus leading to reduction in ENPP2 gene and isoforms expression.
The expression pattern of isoforms differs between tissues as high expression levels of isoform beta were found in peripheral tissues and plasma, while isoform gamma was mostly found in the brain, and isoform alpha is considered to be the most under-expressed in brain and peripheral tissue in comparison to the other two [38]. According to a relevant study, isoform alpha has a deletion of exon 12, isoform beta a deletion of exons 12 and 21 and isoform gamma a deletion of exon 21 [12], leading to different splice variants. None of the identified DMCs were located at these regions, explaining similar patterns of ENPP2 mRNA and isoform expression.
DNA methylation within promoters is known to modulate the binding of TFs to regulatory elements, thus resulting in transcriptional repression [39]. In our study, we predicted 39 TFs which can regulate transcription through binding to ENPP2 promoter’s DMCs. Therefore, any aberrant methylation events in these DMCs during pathological transformation may block TF binding and related transcription. This is further supported by reports involving the identified TFs in ENPP2 and ATX expression. Indeed, among the predicted TFs, NF kappaB, AP-2 and E2F have been previously shown to be sensitive to CG methylation with consequent inhibition of their DNA binding activities [36]. Another TF predicted to bind DMCs of ENPP2, NFAT1, has been shown to mediate ATX overexpression in MDA-MB-435 cells [40]. It has also been shown that blocking the expression of NFAT1 results in downregulation of ATX expression, leading to inhibition of melanoma and metastasis [41]. High C-Jun levels seem to enhance ENPP2 expression [42]. Interestingly, SP was found to regulate ENPP2 transcription in neuroblastoma cells by activating a CRE/AP-1-like element at position −142 to −149 and a GAbox at position −227 to −235 near the TSS of ENPP2 [37]. This is in accordance with our finding that Sp1 can bind near the cg02709432 located at TSS200.
In order to assess any correlation of ENPP2 methylation to tumor prognosis, clinical characteristics analysis was performed and showed that increased methylation of some CGs was correlated with poor tumor parameters. Indeed, in PC it was associated with larger tumors and non-response to pharmacotherapy, in LC it was connected to the advanced cancer stage and in HCC it was associated with macro-invasion. Hence, ENPP2 methylation in the identified CGs could be pursued further and be evaluated in clinical cancer samples as biomarkers of cancer progression and poor outcome. In addition, these results corroborate previous data showing that low mRNA expression was associated with worse prognosis in LC [27].
The involvement of ENPP2 methylation in tumor progression and prognosis was also addressed by analyzing methylomes from cell lines presenting a more or less aggressively invasive phenotype, revealing several DMCs. Higher methylation was observed in the more aggressive in relation to less aggressive HCC and PC cell lines, indicating a connection of ENPP2 methylation with worse prognostic behavior, in accordance with our findings in the clinical samples.
Finally, analysis of colon cell lines treated with DNA methyltransferase inhibitors showed that 5-AZA caused a decrease of methylation in all CGs in relation to untreated controls in the three studied cell lines, showing a clear demethylation effect in the ENPP2 gene. Given the contribution of ENPP2 in a variety of pathologies, further studies could assess a methylation-based reprogramming of ENPP2 via a variety of methylation inhibitors. Similarly, previous studies have demonstrated that targeting the ATX-LPA-LPP axis is an attractive strategy for introducing new therapeutic choices [43][44].
In conclusion, healthy tissues presented increased methylation of ENPP2 in the gene body and decreased in the promoter and 1st exon connected to the active transcription of the gene in most human tissues. A different pattern was described in HCC, melanoma, CRC, LC and PC, showing a malignant-specific profile of ENPP2 methylation. Further analysis of independent TCGA datasets confirmed these results as increased methylation of promoter and 1st exon CGs and decreased ENPP2 mRNA expression in PC and LC in relation to healthy tissues were found. Furthermore, increased methylation of ENPP2 was connected to poor prognostic parameters in the same cancers, which was also supported by analysis of cell line datasets. We also found a negative correlation between mRNA expression at gene and isoform levels and methylation of PA CGs that present TF binding sites. In specific, we postulate that the methylation of promoter CGs may hinder the binding of TFs, and thus, the expression of ENPP2 and isoforms may be reduced.
Our findings contribute to the understanding of methylation events and regulatory mechanism of ENPP2 in cancer and provide a full description of DMCs to be further validated in functional and clinical studies.


  1. Stefan, C.; Jansen, S.; Bollen, M. NPP-type ectophosphodiesterases: Unity in diversity. Trends Biochem. Sci. 2005, 30, 542–550.
  2. Tanaka, M.; Okudaira, S.; Kishi, Y.; Ohkawa, R.; Iseki, S.; Ota, M.; Noji, S.; Yatomi, Y.; Aoki, J.; Arai, H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 2006, 281, 25822–25830.
  3. Ninou, I.; Magkrioti, C.; Aidinis, V. Autotaxin in Pathophysiology and Pulmonary Fibrosis. Front. Med. 2018, 5, 180.
  4. Magkrioti, C.; Galaris, A.; Kanellopoulou, P.; Stylianaki, E.A.; Kaffe, E.; Aidinis, V. Autotaxin and chronic inflammatory diseases. J. Autoimmun. 2019, 104, 102327.
  5. Peyruchaud, O.; Saier, L.; Leblanc, R. Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface. Cancers 2019, 12, 105.
  6. Benesch, M.G.; Tang, X.; Maeda, T.; Ohhata, A.; Zhao, Y.Y.; Kok, B.P.; Dewald, J.; Hitt, M.; Curtis, J.M.; McMullen, T.P.; et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 2014, 28, 2655–2666.
  7. Memet, I.; Tsalkidou, E.; Tsaroucha, A.K.; Lambropoulou, M.; Chatzaki, E.; Trypsianis, G.; Schizas, D.; Pitiakoudis, M.; Simopoulos, C. Autotaxin Expression in Hepatocellular Carcinoma. J. Investig. Surg. 2018, 31, 359–365.
  8. Yang, S.Y.; Lee, J.; Park, C.G.; Kim, S.; Hong, S.; Chung, H.C.; Min, S.K.; Han, J.W.; Lee, H.W.; Lee, H.Y. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 2002, 19, 603–608.
  9. Oikonomou, N.; Mouratis, M.A.; Tzouvelekis, A.; Kaffe, E.; Valavanis, C.; Vilaras, G.; Karameris, A.; Prestwich, G.D.; Bouros, D.; Aidinis, V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 47, 566–574.
  10. Lee, H.Y.; Murata, J.; Clair, T.; Polymeropoulos, M.H.; Torres, R.; Manrow, R.E.; Liotta, L.A.; Stracke, M.L. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem. Biophys. Res. Commun. 1996, 218, 714–719.
  11. Brisbin, A.G.; Asmann, Y.W.; Song, H.; Tsai, Y.Y.; Aakre, J.A.; Yang, P.; Jenkins, R.B.; Pharoah, P.; Schumacher, F.; Conti, D.V.; et al. Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med. Genet. 2011, 12, 156.
  12. Giganti, A.; Rodriguez, M.; Fould, B.; Moulharat, N.; Cogé, F.; Chomarat, P.; Galizzi, J.-P.; Valet, P.; Saulnier-Blache, J.-S.; Boutin, J.A.; et al. Murine and Human Autotaxin α, β, and γ Isoforms: Gene organization, tissue distribution, and biochemical characterization. J. Biol. Chem. 2008, 283, 7776–7789.
  13. Parris, T.Z.; Kovács, A.; Hajizadeh, S.; Nemes, S.; Semaan, M.; Levin, M.; Karlsson, P.; Helou, K. Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas. Oncogenesis 2014, 3, e95.
  14. Razin, A.; Cedar, H. DNA methylation and gene expression. Microbiol. Rev. 1991, 55, 451–458.
  15. Nikolaidis, C.; Nena, E.; Panagopoulou, M.; Balgkouranidou, I.; Karaglani, M.; Chatzaki, E.; Agorastos, T.; Constantinidis, T.C. PAX1 methylation as an auxiliary biomarker for cervical cancer screening: A meta-analysis. Cancer Epidemiol. 2015, 39, 682–686.
  16. Panagopoulou, M.; Esteller, M.; Chatzaki, E. Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine. Cancers 2021, 13, 728.
  17. Panagopoulou, M.; Karaglani, M.; Manolopoulos, V.G.; Iliopoulos, I.; Tsamardinos, I.; Chatzaki, E. Deciphering the Methylation Landscape in Breast Cancer: Diagnostic and Prognostic Biosignatures through Automated Machine Learning. Cancers 2021, 13, 1677.
  18. Panagopoulou, M.; Cheretaki, A.; Karaglani, M.; Balgkouranidou, I.; Biziota, E.; Amarantidis, K.; Xenidis, N.; Kakolyris, S.; Baritaki, S.; Chatzaki, E. Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal Cancer. J. Clin. Med. 2021, 10, 2680.
  19. Panagopoulou, M.; Karaglani, M.; Balgkouranidou, I.; Biziota, E.; Koukaki, T.; Karamitrousis, E.; Nena, E.; Tsamardinos, I.; Kolios, G.; Lianidou, E.; et al. Circulating cell-free DNA in breast cancer: Size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene 2019, 38, 3387–3401.
  20. Panagopoulou, M.; Lambropoulou, M.; Balgkouranidou, I.; Nena, E.; Karaglani, M.; Nicolaidou, C.; Asimaki, A.; Konstantinidis, T.; Constantinidis, T.C.; Kolios, G.; et al. Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2017, 39, 1010428317697557.
  21. Udomsinprasert, W.; Kitkumthorn, N.; Mutirangura, A.; Chongsrisawat, V.; Poovorawan, Y.; Honsawek, S. Association between Promoter Hypomethylation and Overexpression of Autotaxin with Outcome Parameters in Biliary Atresia. PLoS ONE 2017, 12, e0169306.
  22. Liu, X.; Peng, Y.; Wang, J. Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers. Biosci. Rep. 2020, 40.
  23. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  24. Perrakis, A.; Moolenaar, W.H. Autotaxin: Structure-function and signaling. J. Lipid Res. 2014, 55, 1010–1018.
  25. Fuss, B.; Baba, H.; Phan, T.; Tuohy, V.K.; Macklin, W.B. Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J. Neurosci. 1997, 17, 9095–9103.
  26. Kanda, H.; Newton, R.; Klein, R.; Morita, Y.; Gunn, M.D.; Rosen, S.D. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 2008, 9, 415–423.
  27. Nema, R.; Shrivastava, A.; Kumar, A. Prognostic role of lipid phosphate phosphatases in non-smoker, lung adenocarcinoma patients. Comput. Biol. Med. 2021, 129, 104141.
  28. Wang, S.C.; Liao, L.M.; Ansar, M.; Lin, S.Y.; Hsu, W.W.; Su, C.M.; Chung, Y.M.; Liu, C.C.; Hung, C.S.; Lin, R.K. Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of GCM2, ITPRIPL1 and CCDC181 for Detection of Early Breast Cancer and Surgical Treatment Response. Cancers 2021, 13, 1375.
  29. Nouh, M.A.; Wu, X.X.; Okazoe, H.; Tsunemori, H.; Haba, R.; Abou-Zeid, A.M.; Saleem, M.D.; Inui, M.; Sugimoto, M.; Aoki, J.; et al. Expression of autotaxin and acylglycerol kinase in prostate cancer: Association with cancer development and progression. Cancer Sci. 2009, 100, 1631–1638.
  30. Magkrioti, C.; Oikonomou, N.; Kaffe, E.; Mouratis, M.A.; Xylourgidis, N.; Barbayianni, I.; Megadoukas, P.; Harokopos, V.; Valavanis, C.; Chun, J.; et al. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. Cancer Res. 2018, 78, 3634–3644.
  31. Wu, J.M.; Xu, Y.; Skill, N.J.; Sheng, H.; Zhao, Z.; Yu, M.; Saxena, R.; Maluccio, M.A. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol. Cancer 2010, 9, 71.
  32. Maier, T.; Güell, M.; Serrano, L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009, 583, 3966–3973.
  33. Chen, G.; Gharib, T.G.; Huang, C.C.; Taylor, J.M.; Misek, D.E.; Kardia, S.L.; Giordano, T.J.; Iannettoni, M.D.; Orringer, M.B.; Hanash, S.M.; et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteom. MCP 2002, 1, 304–313.
  34. Lemée, J.M.; Clavreul, A.; Aubry, M.; Com, E.; de Tayrac, M.; Mosser, J.; Menei, P. Integration of transcriptome and proteome profiles in glioblastoma: Looking for the missing link. BMC Mol. Biol. 2018, 19, 13.
  35. Arcos-Montoya, D.; Wegman-Ostrosky, T.; Mejía-Pérez, S.; De la Fuente-Granada, M.; Camacho-Arroyo, I.; García-Carrancá, A.; Velasco-Velázquez, M.A.; Manjarrez-Marmolejo, J.; González-Arenas, A. Progesterone Receptor Together with PKCα Expression as Prognostic Factors for Astrocytomas Malignancy. OncoTargets Ther. 2021, 14, 3757–3768.
  36. Tate, P.H.; Bird, A.P. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 1993, 3, 226–231.
  37. Farina, A.R.; Cappabianca, L.; Ruggeri, P.; Di Ianni, N.; Ragone, M.; Merolle, S.; Sano, K.; Stracke, M.L.; Horowitz, J.M.; Gulino, A.; et al. Constitutive autotaxin transcription by Nmyc-amplified and non-amplified neuroblastoma cells is regulated by a novel AP-1 and SP-mediated mechanism and abrogated by curcumin. FEBS Lett. 2012, 586, 3681–3691.
  38. Zhang, X.; Li, M.; Yin, N.; Zhang, J. The Expression Regulation and Biological Function of Autotaxin. Cells 2021, 10, 939.
  39. Héberlé, É.; Bardet, A.F. Sensitivity of transcription factors to DNA methylation. Essays Biochem. 2019, 63, 727–741.
  40. Chen, M.; O’Connor, K.L. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005, 24, 5125–5130.
  41. Braeuer, R.R.; Zigler, M.; Kamiya, T.; Dobroff, A.S.; Huang, L.; Choi, W.; McConkey, D.J.; Shoshan, E.; Mobley, A.K.; Song, R.; et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012, 72, 5757–5766.
  42. Sioletic, S.; Czaplinski, J.; Hu, L.; Fletcher, J.A.; Fletcher, C.D.; Wagner, A.J.; Loda, M.; Demetri, G.D.; Sicinska, E.T.; Snyder, E.L. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J. Pathol. 2014, 234, 190–202.
  43. Benesch, M.G.; Tang, X.; Venkatraman, G.; Bekele, R.T.; Brindley, D.N. Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo. J. Biomed. Res. 2016, 30, 272–284.
  44. Barbayianni, E.; Kaffe, E.; Aidinis, V.; Kokotos, G. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Prog. Lipid Res. 2015, 58, 76–96.
Subjects: Biology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 204
Revisions: 2 times (View History)
Update Date: 11 Nov 2021